Last $51.59 USD
Change Today 0.00 / 0.00%
Volume 0.0
CHGCY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 4:30 PM 04/7/14 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutic-unsp adr (CHGCY) Key Developments

Chugai Pharmaceutical Co. Ltd. Presents at BIO International Convention, Jun-25-2014 04:45 PM

Chugai Pharmaceutical Co. Ltd. Presents at BIO International Convention, Jun-25-2014 04:45 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Chugai Pharmaceutical Co. Ltd. Enters into Licensing Agreement with Roche

Chugai Pharmaceutical Co. Ltd. has entered into a licensing agreement with F. Hoffmann-La Roche Ltd. regarding Chugai's proprietary antibody engineering technologies. Under this license agreement, Chugai grants Roche a license to utilize its antibody engineering technologies and Roche is able to generate innovative antibodies applying this proprietary technologies for Roche's candidates. Roche may also request Chugai to create antibodies for targets that Roche selects. Under the license agreement, Chugai will receive an upfront fee, annual usage fee, and milestone and royalty payments from Roche. With this license agreement, Roche comes to be able to develop antibody drugs which aim for utilizing Chugai's proprietary innovative antibody engineering technologies. In particular, by using these proprietary technologies, it is expected for Roche to have wider choices to select antigens and to achieve therapeutic effects that were not possible by conventional technologies.

Chugai Pharmaceutical Co. Ltd., Q1 2014 Earnings Call, Apr 24, 2014

Chugai Pharmaceutical Co. Ltd., Q1 2014 Earnings Call, Apr 24, 2014

Chugai Pharmaceutical Co. Ltd. Presents at Milken Institute Global Conference 2014, Apr-28-2014 12:00 PM

Chugai Pharmaceutical Co. Ltd. Presents at Milken Institute Global Conference 2014, Apr-28-2014 12:00 PM. Venue: Lon Angeles, California, United States. Speakers: Osamu Nagayama, Chairman of the Board and Chief Executive Officer.

Chugai Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Dividend Guidance for the Second Quarter of Fiscal Year 2014 and Full Year Ending December 2014; Provides Earnings Guidance for the First Three Months of Fiscal Year 2014 and Full Year Ending December 2014

Chugai Pharmaceutical Co. Ltd. reported consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenues of JPY 124,045 million compared to JPY 124,045 million a year ago. Operating profit was JPY 31,089 million compared to JPY 14,663 million a year ago. Profit before taxes was JPY 31,263 million compared to JPY 13,660 million a year ago. Net income was JPY 19,080 million compared to JPY 9,190 million a year ago. Net income attributable to the company shareholders was JPY 18,776 million compared to JPY 8,897 million a year ago. Diluted net income per share was JPY 34.41 compared to JPY 16.33 a year ago. Cash flows from operating activities were JPY 15.4 million compared to JPY 14.0 million. Free cash flows were a net cash outflow of JPY 3.6 billion. The company provided dividend guidance for the second quarter of fiscal year 2014 and full year ending December 2014. For the quarter, the company expects dividend of JPY 22.00 per share. Dividend for the same period previous year was JPY 22.00 per share. For the year ending December 2014, the company expects dividend of JPY 23.00 per share. Dividend for the same period previous year was JPY 23.00 per share. The company provided earnings guidance for the first three months of fiscal year 2014 and full year ending December 2014. For the first three months, the company expects revenues of JPY 124,045 million, core operating profit of JPY 31,448 million and core earnings per share of JPY 34.82. For the fiscal year ending December 2014, the company expects revenues of JPY 451,000 million, core operating profit of JPY 71,000 million and core earnings per share of JPY 82.62.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHGCY:US $51.59 USD 0.00

CHGCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.24 USD -0.03
Bristol-Myers Squibb Co $48.51 USD +0.59
Eli Lilly & Co $62.53 USD -0.09
Merck KGaA €63.96 EUR +0.28
Teva Pharmaceutical Industries Ltd $54.00 USD +0.13
View Industry Companies
 

Industry Analysis

CHGCY

Industry Average

Valuation CHGCY Industry Range
Price/Earnings 25.9x
Price/Sales 3.4x
Price/Book 2.7x
Price/Cash Flow 26.6x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTIC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.